GlassScriptPhysician profile
Delcine A Sood
NPI 1417148362
$3,591.81
in general payments reported to CMS, 2019-2025
23 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $141 · 2021: $377 · 2022: $613 · 2023: $826 · 2024: $743 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.90 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $767.04 | 2022-2024 | |
| Boston Scientific Corporation | $637.14 | 2021-2025 | Watchman Access System, General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $567.78 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $399.13 | 2019-2025 | Lifevest |
| Abbott Laboratories | $371.66 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $257.81 | 2022-2025 | Repatha |
| Esperion Therapeutics, INC. | $114.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.75 | 2019-2024 | |
| Preventice Services, LLC | $51.03 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.33 | 2023-2024 | Farxiga |
| Pfizer INC. | $40.07 | 2019-2023 | |
| Heartflow, INC. | $38.39 | 2022 | |
| Irhythm Technologies, INC. | $34.50 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2023 | Jardiance |
| Impulse Dynamics (USA) INC. | $32.14 | 2025 | Optimizer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.49 | 2023-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $20.97 | 2022 | |
| W. L. Gore & Associates, INC. | $19.26 | 2022 | |
| Kestra Medical Technology Services, INC. | $18.33 | 2023 | Assure Wcd |
| Novo Nordisk INC | $16.47 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $15.46 | 2024 | Evkeeza |
| Janssen Pharmaceuticals, INC | $15.23 | 2019 | |
| Teleflex LLC | $14.92 | 2025 | Trapliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delcine Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.